Top news of the week: 24.01.2023.
Can BiologIC’s Biocomputer Help Bring Biomanufacturing To Space?
BiologIC Technologies, a company out of Cambridge, UK, wants to bring disruptive innovation to biomanufacturing with the world's first biocomputer.
Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant
This year could stay turbulent for the biotech sector as investors look for what the Roivant CEO described in an interview with BioPharma Dive as “safe harbors in a storm.”
Temasek, Toyota back climate biotech firm Living Carbon
Singapore state-owned investment company Temasek has led the latest funding round for climate tech firm Living Carbon, which aims to increase the carbon-absorbing ability of trees, the ...
University Of Virginia Receives Historic $100 Million Gift For New Biotechnology Institute
The University of Virginia (UVA) has announced that it is launching a biotechnology institute, funded in large measure by a $100 million donation from Charlottesville entrepreneur and ...
50 Over 50: Europe, Middle East And Africa 2023
Women around the world are proving that success has no age limit. The members of the second annual 50 Over 50: EMEA are proving that every day. Here are the founders, business and political ...
Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection
Pulmobiotic is a spin off company from the Centre for Genomic Regulation (Barcelona - Spain) founded by experienced entrepreneurs and funded by invivo Ventures. Pulmobiotics will use its ...
EQRx promised to deliver cutting-edge drugs at half the cost of rivals. A cofounder shares why the once buzzy biotech is walking away from that mission
EQRx's Alexis Borisy told Insider that regulatory delays, caused by reliance on China-based data, had changed EQRx's pricing strategy.
3 biotech executives on the year ahead: deals, drug pricing and the down market
“What we’re experiencing now is the aftershock of the party that went on for the last three years,” said Ovid CEO Jeremy Levin in a BioPharma Dive panel that included former Sage head Jeff ...